NCT06791525
Tirbanibulin for Pediatric Warts
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 9 words Show 4 more changesShow less
- Trial completed
- Final enrollment: 7 participants (planned 10)
- Study completion date changed from estimate of Dec 30, 2026 to Nov 5, 2026
- Site details revised
- Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
- Study completion date: Dec 30, 2025 to Dec 30, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Mar 1, 2025 to May 1, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Resolution
Timeframe: 2 months aftre completion of 4 or less treatment cycles
Arms and interventions
Topical treatment armExperimental
Topical medication self-applied
Drugs: Tirbanibulin ointment 1%
Sites
1 site in 1 country
- The Skin Center Dermatology GroupNew City, New York, United States